a patient with hepatocellular carcinoma (hcc) treated with nivolumab (opdivo) post sorafenib
Published 4 years ago • 70 plays • Length 2:53Download video MP4
Download video MP3
Similar videos
-
1:00
prime-hcc: ipilimumab and nivolumab in liver cancer
-
4:33
results from a phase iii study of sorafenib and sbrt for hepatocellular carcinoma
-
2:28
nrg/rtog 1112: sorafenib vs sbrt followed by sorafenib in hcc
-
1:40
comparing sorafenib and lenvatinib for the frontline treatment of advanced hcc
-
1:36
cabozantinib in patients with hcc refractory to checkpoint inhibitors
-
5:26
hcc whiteboard #1: the epidemiology of hepatocellular carcinoma and current standard of care
-
1:01
dr. heymach on nivolumab for lung cancer
-
6:02
hcc: considerations in first-line use of sorafenib
-
2:52
refine: a real-world analysis of regorafenib in patients with unresectable hcc
-
1:05:05
hcc: optimizing outcomes with new and emerging treatment approaches
-
5:59
frontline lenvatinib vs sorafenib in hcc
-
2:09
keynote-240: pembrolizumab in advanced hcc
-
1:48
addressing how to treat patients with advanced hepatocellular carcinoma
-
1:27
takeaways in hepatocellular carcinoma at asco gi 2023
-
7:52
latest in hepatocellular carcinoma treatments
-
1:46
results from the celestial trial for patients with advanced hcc
-
6:25
checkmate 459: long-term survival outcomes with nivolumab versus sorafenib as first-line treatme...
-
1:15
expert addresses sequencing challenge in hcc
-
8:10
dosing strategies with sorafenib in hcc